Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expects Sustainable Revenue Growth, Plans New Capital Markets Strategy in 2020
Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed…